Prasinezumab (Prx002) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Prasinezumab (PRX002) is a humanized monoclonal antibody designed to target and clear pathological [alpha-synuclein](/proteins/alpha-synuclein) aggregates in Parkinson's disease and other synucleinopathies. Developed by Prothelia in partnership with Roche, it represents one of the most advanced immunotherapeutic approaches targeting alpha-synuclein pathology. [@pagano2024]
Overview
Mechanism of Action
Prasinezumab is a humanized IgG1 monoclonal antibody that specifically binds to the C-terminus of alpha-synuclein:
1. Target Selection
Binds to aggregated and oligomeric alpha-synuclein with high affinity (picomolar range)
Epitope chosen to specifically target pathogenic forms while sparing normal monomeric alpha-synuclein
Recognizes conformational epitopes unique to aggregated species
2. Peripheral Sequestration
Captures extracellular alpha-synuclein in the bloodstream
Reduces free serum alpha-synuclein by up to 97%
Acts as a "sink" to draw alpha-synuclein from the CNS
3. Fc-Mediated Clearance
Activates [microglia](/entities/microglia) via Fcγ receptors to clear antibody-opsonized aggregates
Enhances phagocytosis of toxic species
Promotes antigen presentation and adaptive immune response
4. Prion-Like Propagation Blockade
Prevents uptake of toxic seeds by healthy [neurons](/entities/neurons)
Blocks intercellular transmission of alpha-synuclein pathology
May protect previously unaffected brain regions
Rationale for C-Terminal Targeting
The C-terminal region of alpha-synuclein (residues 109-132) was chosen as the antibody epitope because:
It is exposed in aggregated and oligomeric forms
It is relatively protected in monomeric alpha-synuclein
It is involved in membrane binding and aggregation nucleation
Antibodies targeting this region show good blood-brain barrier penetration
Clinical Development
Phase 1 Studies (PRX002-001)
Design: Single and multiple ascending dose studies in healthy volunteers and PD patients
Key Results:
Demonstrated significant reduction in free serum alpha-synuclein (up to 97%)
Good safety and tolerability profile at all doses tested
Dose-dependent pharmacokinetics
Dose selection for Phase 2 based on PK/PD modeling
The study of Prasinezumab (Prx002) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions